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High-Sensitivity Troponin T and C-Reactive Protein Have Different
Prognostic Values in Hemo- and Peritoneal Dialysis Populations:
A Cohort Study
Titi Chen, MBBS, FRACP; Hicham C. Hassan, MBBS, FRACP; Pierre Qian, MBBS, FRACP; Monica Vu, MBBS; Angela Makris, MBBS, PhD,
FRACP
Background-—Dialysis patients have an exceedingly high mortality rate. Biomarkers may be useful tools in risk stratiﬁcation of this
population. We evaluated the prognostic value of high-sensitivity cardiac troponin T (hs-cTnT) and CRP (C-reactive protein) in
predicting adverse outcomes in stable hemodialysis and peritoneal dialysis (PD) patients. Variability in hs-cTnT was also examined.
Methods and Results-—A retrospective cohort study included 574 dialysis patients (hemodialysis 347, PD 227). Outcomes
examined included mortality and major adverse cardiovascular events, with median follow-up of 3.5 years. hs-cTnT was an
independent predictor of both outcomes in hemodialysis and PD patients. Increased risk only became signiﬁcant when hs-cTnT
reached quintile 3 (>49 ng/L). Area under the receiver operating curve analysis showed that the addition of hs-cTnT to clinical
parameters signiﬁcantly improved its prognostic performance for mortality in PD patients (P=0.002). CRP was an independent
predictor of both outcomes in PD patients only. Only CRP in the highest quintile (>16.8 mg/L) was associated with increased risk.
hs-cTnT remained relatively stable for the whole follow-up period for hemodialysis patients, whereas for PD patients, hs-cTnT
increased by 23.63% in year 2 and 29.13% in year 3 compared with baseline (P<0.001).
Conclusions-—hs-cTnT and CRP are useful tools in predicting mortality and major adverse cardiovascular events in hemodialysis
and PD patients. Given that hs-cTnT levels increase over time in PD patients, interval monitoring may be valuable for risk
assessment. In contrast, hs-cTnT in hemodialysis patients has little interval change and progress monitoring is not indicated. ( J
Am Heart Assoc. 2018;7:e007876. DOI: 10.1161/JAHA.117.007876.)
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T he mortality rate of the dialysis population far exceedsthat of the general population.1 Traditional cardiovascu-
lar disease risk factors are common in end-stage kidney
disease patients, but do not fully explain the high mortality
rate.2 Nontraditional factors, such as chronic low-grade
inﬂammation, are important characteristics of end-stage
kidney disease patients and have contributed to the high
mortality rate.2,3 Given that traditional risk factors are
inadequate at predicting adverse outcome in the dialysis
population, serum biomarkers can be a useful tool in risk
stratifying these patients.
Troponin is a powerful predictor of cardiovascular and all-
cause mortality.4 Most of the studies investigating troponin
were performed using traditional troponin assay and on
hemodialysis patients.4,5 Information on peritoneal (PD)
patients is lacking. The high-sensitivity cardiac troponin T
(hs-cTnT) assay introduced in recent years has a greater
sensitivity for cardiac myocyte necrosis.6,7 There is a paucity
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of information regarding the prognostic value of hs-cTnT in the
dialysis population.
CRP (C-reactive protein) is also a powerful predictor of
clinical outcomes in the general population8,9 and patients on
dialysis.10–12 As with the studies for troponins, most of these
studies were performed on hemodialysis patients, with
information on PD patients lacking.
Previously, we conducted a 1-year prospective study
investigating the prognostic values of hs-cTnT in predicting
adverse outcomes. In the current study, we investigated a
larger sample size with a longer follow-up of 3.5 years to
evaluate the prognostic value of hs-cTnT and CRP in
predicting major adverse cardiovascular events (MACE) or
death. Furthermore, we also compared the prognostic value of
hs-cTNT with CRP and traditional clinical parameters and
studied the variability of hs-cTnT over time.
Methods
The data, analytical methods, and study materials are
available from the corresponding author on reasonable
request.
Study Cohort
The study was approved by the South Western Sydney Local
Health District Human Research Ethics Committee, and the
requirement for informed consent was waived. We included
574 patients receiving dialysis in a tertiary metropolitan
hospital network (Sydney, NSW, Australia) between July 2011
and January 2015. All of them were followed up until January
2015. Of these patients, 347 of them started dialysis before
July 2011, and 227 started dialysis after July 2011. Inclusion
criteria were: aged ≥18 years and had been undergoing
dialysis for >2 weeks. Patients were excluded if there was no
blood test performed or if they were hospitalized in the week
before baseline blood tests, were pregnant, or had a known
acute systemic inﬂammatory disorder or active infection.
Blood Sampling and Analysis
hs-cTnT and CRP were measured as part of the protocol at
patients’ routine yearly blood tests. For hemodialysis patients,
blood was taken before the start of the second dialysis session
of the week through the patient’s dialysis access. PD patients’
blood samples were taken by a BD Vacutainer system (BD
Biosystems, San Jose, CA) during their monthly outpatient
visits. hs-cTnT level was repeated on a yearly basis. Assays
were performed using a ﬁfth-generation electrochemilumines-
cence assay (Elecsys, Cobas 8000, e602 analyzer; Roche
Diagnostics, Indianapolis, IN) in an accredited laboratory
(National Association of Testing Authorities, Australia).13
According to the manufacturer of the assay, limit of detection
was 5 ng/L, the 99th percentile upper reference limit was
14 ng/L in the normal population, the analytical range was 3 to
10 000 ng/L, and the coefﬁcient of variation was <10% at the
lowest concentration of 13 ng/L. CRP was measured using
Roche Cobas 8000 c702 (Roche Diagnostics), with a detection
range of 0.3 to 350 mg/L. Laboratory personnel were blinded
to patients outcome data or history at the time of assay.
Data Collection, Outcomes, and Deﬁnitions
Baseline characteristics and outcome data were obtained from
electronic medical records and hospital databases. Personnel
who collected such data were blinded to patients’ blood test
results. Outcomes analyzed were all-cause mortality and
MACE, and the change in hs-cTnT over the 3.5-year follow-up
was also examined. Patients were censored for further follow-
up if they underwent kidney transplantation, were transferred
to another dialysis unit, or changed dialysis modality.
The deﬁnition of MACE was cardiac death, nonfatal
myocardial infarction, or target lesion revascularization.
Myocardial infarction was deﬁned by a rise in hs-cTnT
(>20% increase from a previous baseline) in addition to
Clinical Perspective
What Is New?
• Increased level of high-sensitivity cardiac troponin T (hs-
cTnT) was an independent predictor for mortality and major
adverse cardiovascular events in both hemodialysis and
peritoneal dialysis patients.
• CRP (C-reactive protein) was an independent predictor for
mortality and major adverse cardiovascular events in
peritoneal dialysis patients only.
• Increased risk of adverse outcome was not linearly related
to increased hs-cTnT and CRP.
• For hs-cTnT, risk did not become signiﬁcant until hs-cTnT
reached quintile 3 (>49 ng/L), whereas for CRP, only
quintile 5 (>16.8 mg/L) was associated with increased risk.
• There was a signiﬁcant increase in hs-cTnT level in
peritoneal dialysis patients over time, wheras for hemodial-
ysis patients, hs-cTnT level remained relatively stable.
What Are the Clinical Implications?
• hs-cTnT and CRP are useful tools in predicting mortality and
major adverse cardiovascular events in the dialysis popu-
lation at 3.5 years.
• The prognostic value of hs-cTnT is better than CRP.
• The frequency of hs-cTnT measurement should be at least
yearly for peritoneal dialysis patients to establish baseline
given the level increases signiﬁcantly.
• For hemodialysis patients, a less-frequent measurement
may be acceptable as the change over time is minimal.
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ischemic symptoms, new ECG changes, or identiﬁcation of an
intracoronary thrombus by angiography.14 Cardiac mortality
was deﬁned as any death with a demonstrable cardiovascular
cause or sudden cardiac death. Coronary heart disease (CHD)
included diagnosis of myocardial infarction, angina pectoris,
and silent myocardial ischemia. Combined clinical parameters
used in the analysis included age, sex, dialysis vintage, history
of diabetes mellitus, CHD, and peripheral vascular disease.
Statistical Analysis
Continuous variables are presented as mean with SD or
median with interquartile range (IQR). Distributions between
groups were compared using the Student t test or Mann–
Whitney U test, ANOVA, or Kruskal–Wallis tests, as appropri-
ate. Categorical variables are presented as frequency (%), and
the association between categorical variables was assessed
using the chi-square test. Strength of association between hs-
cTnT and CRP was quantiﬁed using Spearman rank correla-
tion. Kaplan–Meier time-to-event curves with log-rank test
were used to compare outcomes across hs-cTnT and CRP
quintiles. Univariable and multivariable Cox proportional
hazard models were used to estimate time to all-cause
mortality or MACE and hazard ratio (HR) with 95% conﬁdence
interval (CI) were calculated. Step-wise backward regression
analysis was used to identify variables that were independent
predictors of outcomes. Variables shown to be signiﬁcant in
the univariable analysis were included in the backward
regression model. Probabilities for entry or removal from
the model were 0.050 and 0.100, respectively.
For analysis of the prognostic performance of hs-cTnT and
CRP using receiver operating characteristics (ROC) curves at
3.5 years and variability in hs-cTnT over this period of time,
we only included 347 patients who were already on dialysis in
July 2017. ROC curves were calculated for the prognostic
performance of hs-cTnT, CRP, and combined clinical param-
eters. Area under the ROC curve (AUC) was used to quantify
the global prognostic performance of each of these variables.
We also investigated whether adding hs-cTnT to clinical
parameters improved the prognostic performance of clinical
parameters. AUC was compared using the method described
by Delong et al.15
We ﬁtted a linear mixed-effects model to investigate the
variability of hs-cTnT level over time. hs-cTnT levels were log
transformed to approximate normality and stabilize the
variance before analysis. Patient identiﬁer was considered
as a random effect, type of dialysis as a ﬁxed effect, and year
since baseline troponin as both a ﬁxed effect and as a random
effect with a general positive deﬁnite covariance structure.
Parameter estimates and their 95% CIs were back-trans-
formed to present results as percentage change from
baseline.
IBM SPSS (version 23; IBM Corp, Armonk, NY) and R
software (version 3.3.1; R Foundation for Statistical Comput-
ing, Vienna, Austria) were used to analyze the data. A P value
of <0.05 was considered statistically signiﬁcant.
Results
Clinical Characteristics and Outcomes
A total 574 patients were included, of whom 347 were on
hemodialysis and 227 were on PD (Figure 1). Of the patients
assessed for eligibility, 158 were excluded. No patient was
lost to follow-up.
Baseline characteristics of these patients were summa-
rized in Table 1. Median age was 66.0 (IQR, 55.0–73.5) years,
with 342 (59.6%) of these patients being male. Median
duration of dialysis was 1.3 (IQR 0.3–3.6) years, and 228
(39.7%) had a history of CHD. During a median follow-up of
3.5 years, there were 176 (30.6%) deaths, of which 60 were
attributed to cardiac causes. One hundred eleven (19.3%)
patients experienced MACE.
Baseline hs-cTnT and CRP Levels
Median hs-cTnT for the total cohort was 59 ng/L (IQR, 3,6–97).
Only 17 patients (3%) had hs-cTnT below the upper reference
limit for the normal population (14 ng/L). In the subpopulation
of patient without CHD, 15 (6.6%) had hs-cTnT below the upper
reference limit. Hemodialysis patients had higher hs-cTnT than
PD patients (63 versus 55 ng/L; P=0.011).
Patients were divided into quintiles based on their hs-cTnT
level. Clinical characteristics associated with higher hs-cTnT
quintiles were older age (P<0.001), male sex (P<0.001),
history of diabetes mellitus (P<0.001), respiratory disease
(P=0.041), and CHD (P<0.001; Table S1).
Median CRP for the total cohort was 4.9 mg/L (IQR, 2.0–
2.7). Two hundred ninety-three patients (52%) had a CRP
below the upper reference limit of 5 mg/L. Hemodialysis
patients had a higher CRP than PD patients (6.1 versus
3.5 mg/L; P<0.001). Clinical characteristics associated with
higher CRP quintiles were CHD (P<0.001) and longer dialysis
vintage (P=0.009; Table S2).
There was no signiﬁcant association between hs-cTnT
and CRP level (total cohort Spearman rank correlation,
0.080; P=0.060; hemodialysis Spearman rank correlation,
0.068; P=0.209; PD Spearman rank correlation, 0.037;
P=0.574).
Variability in hs-cTnT Over Time
We investigated the variability in hs-cTnT level over time.
For hemodialysis patients, hs-cTnT remained relatively
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stable for the whole follow-up period compared with
baseline. For PD patients, hs-cTnT increased by 23.63% in
year 2 (P<0.001) and 29.13% in year 3 (P<0.001) compared
with baseline.
Hs-cTnT and CRP as Predictors of Outcomes
Survival analysis
Figure 2 illustrated the Kaplan–Meier curves of outcomes
based on hs-cTnT. hs-cTnT in the ﬁrst quintile (<32 ng/L)
was associated with the best outcome whereas hs-cTnT in
the ﬁfth quintile (>108 ng/L) was associated with the worst
outcome for both mortality (log-rank P<0.001) and MACE
(log-rank P<0.001). PD and hemodialysis subgroup analysis
results were similar (mortality P<0.001 for both PD and
hemodialysis, MACE P=0.004 for PD, 0.006 for
hemodialysis).
Kaplan–Meier curves based on CRP quintiles showed that
higher CRP quintiles were associated with increased risk of
mortality in both PD (P<0.001) and hemodialysis (P=0.042)
patients. With regard to MACE, higher CRP quintiles were
associated with increased risk in PD patients (P=0.002) only,
but not in hemodialysis patients.
Univariable analysis
Table 2 presented the HR with associated CI for mortality and
MACE from univariable analysis. Higher hs-cTnT quintiles
predicted increased risk of mortality and MACE compared
with the lowest quintile. The highest risk was in the ﬁfth
quintile (>108 ng/L), with mortality HR of 3.67 and MACE HR
of 3.90. With regard to CRP, only the highest quintile
(>16.8 mg/L) was predictive of both mortality (P<0.001) and
MACE (P=0.008). Subgroup analysis of hemodialysis and PD
patients showed a similar result for hs-cTnT. However, for
CRP, it was not a predictor for MACE in hemodialysis patients.
Multivariable analysis
When analyzing mortality as the outcome (Table 2), in the
total cohort, older age (P<0.001), malignancy (P=0.046),
longer dialysis vintage (P=0.020), lower albumin (P=0.002),
and higher hs-cTnT and CRP remained statistically signiﬁcant
independent predictors. In hemodialysis patients (Table 3),
!
Excluded n= 158 (96HD, 62PD)
Hospitalized week before baseline blood n=34 (19HD,
15PD)
Acute systematic inflammatory disorder or infection
n=22 (14HD, 8PD)
Acute dialysis (less than two weeks) n=19 (11HD, 8PD)
No baseline hs-cTnT performed  n=82 (51HD, 31PD)
Pregnant n=1 (1HD)
Assessed for eligibility 
n=732 (443HD, 289PD)
HD Patients
n=347
Total recruited
n=574
PD Patients
n=227
Figure 1. Flow diagram for patients included in the study. HD indicates hemodialysis; PD, peritoneal
dialysis.
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older age (P<0.001), CHD (P=0.008), longer dialysis vintage
(P=0.045), lower albumin (P=0.007), and higher hs-cTnT were
independent predictors, whereas in PD patients, older age
(P=0.004), lower albumin (P=0.031), and higher hs-cTnT and
CRP were independent predictors.
Similar analysis was performed for MACE. In the combined
population, CHD (P=0.046), respiratory disease (P=0.019),
peripheral vascular disease (P=0.001), and higher hs-cTnT
were shown to be independent predictors for MACE. In
hemodialysis patients (Table 3), CHD (P=0.045), respiratory
disease (P=0.031), peripheral vascular disease (P=0.024),
lower albumin (P=0.040), and higher hs-cTnT were indepen-
dent predictors, whereas in PD patients, higher hs-cTnT and
CRP were independent predictors.
We also analyzed the subgroup of patients without CHD
(n=346; Table 4) and found that higher hs-cTnT was an
independent predictor for both mortality and MACE.
Area under the receiver operating curve analysis
ROC curve was used to compare the prognostic performance
of hs-cTnT, CRP, and combined clinical parameters and to
investigate whether adding hs-cTnT to clinical parameters
further improves risk stratiﬁcation for prediction of mortality
and MACE (Table 5). AUC for CRP, hs-cTnT, and combined
clinical parameters were 0.59 (95% CI, 0.54–0.64), 0.71 (95%
CI, 0.66–0.75), and 0.70 (95% CI, 0.65–0.75), respectively, for
mortality and 0.52 (95% CI, 0.47–0.58), 0.62 (95% CI, 0.57–
0.67), and 0.63 (95% CI, 0.58–0.69) for MACE. Both hs-cTnT
and clinical parameters have larger AUC than CRP for
mortality and MACE. There was no signiﬁcant difference
between AUC for hs-cTnT and clinical parameters. In the
combined population, adding hs-cTnT to clinical parameters
signiﬁcantly increased AUC for mortality (P=0.012), but not
MACE. In the subgroup analysis of hemodialysis and PD
Table 1. Baseline Characteristics and Outcomes of the Study Population
Variables All Group (N=574) Hemodialysis (N=347) PD (N=227) P Value
Age, y 66.0 (55.0–73.5) 65.8 (55.0–73.5) 66.0 (56.0–73.8) 0.707
Sex, male 342 (59.6) 203 (58.5) 139 (61.2) 0.514
Comorbidities (N=570)
Diabetes mellitus 310 (54.0) 198 (57.6) 112 (49.3) 0.061
CHD 228 (39.7) 141 (40.6) 87 (38.3) 0.552
Hepatitis B or C 31 (5.4) 24 (6.9) 7 (3.1) 0.046
DVT/PE 33 (5.7) 21 (6.1) 12 (5.3) 0.691
Malignancy 69 (12.1) 45 (13.0) 24 (10.6) 0.378
Respiratory 85 (14.8) 58 (16.7) 27 (11.9) 0.107
Neurological 76 (13.2) 41 (11.8) 35 (15.4) 0.220
PVD 42 (7.3) 34 (9.8) 8 (3.5) 0.005
Laboratory values
hs-cTnT, ng/L (N=574) 59 (36–97) 63 (38–103) 55 (32–86) 0.011
Albumin, g/L 39 (36–42) 40 (37–43) 38 (34–41) <0.001
Calcium, mmol/L 2.28 (2.16–2.38) 2.25 (2.14–2.37) 2.31 (2.21–2.42) 0.001
Phosphate, mmol/L 1.65 (1.32–2.07) 1.63 (1.25–1.98) 1.72 (1.40–2.15) 0.006
Magnesium, mmol/L 0.90 (0.81–1.00) 0.93 (0.84–1.04) 0.88 (0.76–0.95) <0.001
Hemoglobin, g/L 113 (103–124) 114 (104–124) 112 (102–123) 0.467
CRP, mg/L (N=565) 4.9 (2.0–12.7) 6.1 (2.6–16.5) 3.5 (1.6–9.2) <0.001
PTH, pmol/L 32.5 (14.5–57.2) 35.4 (13.7–69.1) 31.6 (15.6–48.4) 0.240
Dialysis vintage, y 1.3 (0.3–3.6) 2.16 (0.51–5.11) 0.75 (0.08–2.09) <0.001
Outcomes
Mortality 176 (30.6) 119 (34.3) 57 (25.1) 0.020
MACE 111 (19.3) 80 (23.1) 31 (13.7) 0.005
Data are expressed as n (%), median (interquartile range), or mean (SD) depending on normality tests. Statistical signiﬁcance was assessed between hemodialysis and PD groups. CHD
indicates coronary heart disease; CRP, C-reactive protein; DVT, deep vein thrombosis; hs-cTnT, high-sensitivity cardiac troponin T; MACE, major adverse cardiovascular events; PD,
peritoneal dialysis; PE, pulmonary embolism; PTH, parathyroid hormone; PVD, peripheral vascular disease.
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patients, adding hs-cTnT to clinical parameters increased AUC
for mortality in PD patients (P=0.002), but not hemodialysis
patients. Adding CRP to clinical parameters did not increase
AUC.
Discussion
We reported several important ﬁndings in this study. First, hs-
cTnT and CRP levels and their prognostic performance were
signiﬁcantly different in PD compared with hemodialysis
patients. PD patients had lower hs-cTnT and CRP than
hemodialysis patients. In PD patients, both hs-cTnT and CRP
were independent predictors for mortality and MACE whereas
for HD patients, only hs-cTnT was an independent predictor.
There was a signiﬁcant increase in hs-cTnT level in PD patients
over time. However, for hemodialysis patients, hs-cTnT level
remained relatively stable. Second, the increased risk of
adverse outcome was not linearly related to increased hs-cTnT
and CRP. For hs-cTnT, the risk did not become signiﬁcant until
hs-cTnT reached quintile 3 (>49 ng/L) whereas for CRP, only
quintile 5 (>16.8 mg/L) was associated with increased risk.
hs-cTnT as a Predictor of Outcomes
We established that increased level of hs-cTnT was associated
with a higher risk of mortality and MACE. Troponin has been
extensively studied in patients with chronic kidney disease
prompting 2 meta-analyses.4,5 However, very few studies
were performed with hs-cTnT. The studies that were per-
formed with hs-cTnT, including the 1 we previously conducted,
were limited by smaller sample size or shorter follow-up
period.16–20 In addition, information on PD patients is lacking.
There have not been any studies assessing the association
between hs-cTnT and MACE, and there is also a lack of
information regarding the variability in hs-cTnT over time. Our
current study has addressed all of these issues and shown
that hs-cTnT is an independent predictor for mortality and
MACE in both HD and PD patients at 3.5-year follow-up.
Compared with older troponin T assays that were reported
to be elevated in up to 82% of the dialysis population,21 we
found an even higher proportion with elevated hs-cTnT (97%),
which is consistent with other studies performed on hs-
cTnT.16,18,22 Previous studies on hs-cTnT analyzed it as a
continuous variable.16,17 We have shown that the increased
risk of adverse outcomes with increased hs-cTnT quintiles did
not follow a linear relationship. The increased risk only
became signiﬁcant when hs-cTnT reached quintile 3 (>49 ng/
L), and there was a signiﬁcant step up in HR when hs-cTnT
increased from quintile 4 (73–108 ng/L) to quintile 5
(>109 ng/L).
Patients in the highest quintile of hs-cTnT may require
special attention. This group of patients had the highest HR,
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Figure 2. Kaplan–Meier curves based on quintiles of hs-cTnT for mortality (A and B) and MACE (C and D).
HD indicates hemodialysis; hs-cTnT, high-sensitivity cardiac troponin T; MACE, major adverse cardiovas-
cular events; PD, peritoneal dialysis; Q, troponin quintile.
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which almost doubled that of the fourth quintile. They had an
extremely high mortality (53.5%) and MACE (32.5%) rate at
3.5 years. Interestingly, their age was not particularly
advanced, with a median age of 65. Therefore, selectively
targeting this group of patients for prevention or more-
intensive intervention may be particularly beneﬁcial.
We also investigated the variability in hs-cTnT level over
the 3.5-year period. The pattern of change in hs-cTnT level
was different in hemodialysis and PD patients. Surprisingly,
hs-cTnT did not change in hemodialysis patients, whereas in
PD patients, it increased signiﬁcantly from year 2. There has
only been 1 study investigating the variability in hs-cTnT in
hemodialysis only over 1 month and showed no change.16
This has implications on the frequency of hs-cTnT monitoring.
For PD patients, yearly measurements at least are necessary
to establish baseline. For hemodialysis patients, a less-
frequent measurement may be acceptable. Further study is
needed to determine whether variation in hs-cTnT over time
can provide additional prognostic information.
CRP as a Predictor of Outcomes
Inﬂammation has been recognized as an essential component
of chronic kidney disease attributed to a variety of reasons.3
Low-grade inﬂammation is associated with increased
atherosclerotic risk and mortality.11,23,24 Despite novel
inﬂammatory markers being described in recent years, CRP
remains the most measured of inﬂammatory markers. Use of
CRP has increased signiﬁcantly over the last decade, and
dialysis units measuring CRP in more than 50% of their
dialysis patients had lower cardiovascular-related mortality.25
We evaluated the prognostic value of CRP and compared it
with hs-cTnT. Consistent with other studies, we found that
CRP was an independent predictor in PD patients only. We are
the ﬁrst study to analyze CRP in quintiles because it was not
normally distributed, and found that the increased risk of
adverse outcomes with increased CRP quintiles only became
statistically signiﬁcant when CRP reached quintile 5
(>16.8 mg/L). Prognostic performance of CRP was inferior
to hs-cTnT. Adding CRP to clinical parameters did not improve
its prognostic value.
Hemodialysis Patients
For hemodialysis patients, hs-cTnT level was an independent
predictor of mortality and MACE, together with known clinical
factors like CHD. This result is consistent with previous
studies, which found hs-cTnT to be predictive of mortality in a
combined PD and hemodialysis population at 3 years,17
cardiovascular mortality for hemodialysis at 6 months,16 and
all-cause mortality for hemodialysis at 2 years.18 We have
shown this to be true for both hemodialysis and PD patients atT
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3.5-year follow-up. This is the ﬁrst study to show that hs-cTnT
is also an independent predictor of MACE. These ﬁndings are
inconsistent with Voroneanu et al, who found that hs-cTnT
was not an independent predictor for all-cause mortality in
hemodialysis patients at 24 months.20 This inconsistency
could be attributed to the difference in sample size, follow-up
period, and analysis method.
For hemodialysis patients, we found that CRP was not an
independent predictor for mortality or MACE. Our result is
consistent with 1 other study with follow-up of 10 years,
which showed that CRP was not a signiﬁcant predictor for
mortality.26 However, this is contrary to other studies, which
showed that CRP was predictive of mortality at 124 and
2 years.11,25,27 The difference may be attributed to the longer
follow-up period in our study, and level of CRP may be
inﬂuenced by many processes and ﬂuctuate signiﬁcantly over
time. It has been shown that CRP is only a good predictor of
risk in the short term (1 year of follow-up).28 Over longer
periods, given that other factors inﬂuence a patient’s
prognosis, the association between CRP and mortality
weakens.29 Therefore, it has been proposed that repeated
measurement of CRP may be more useful than a single
measurement.29
PD Patients
There is a paucity of evidence regarding the use of biomarkers
in risk stratiﬁcation of PD patients. We have previously
demonstrated that hs-cTnT is an independent predictor of
cardiac events and mortality at 1 year.30 The current study
has shown this to be true at 3.5 years. There has been only 1
previous study assessing CRP for prediction of mortality in PD
patients,31 which showed it to be a signiﬁcant predictor at
2-year follow-up. We conﬁrmed this result at 3.5-year follow-
up, and, in addition, it is also a predictor for MACE. We
demonstrated the prognostic value of hs-cTnT, and CRP was
Table 3. Multivariable Analysis With Cox Proportional Hazard Model to Examine Variables Inﬂuencing Mortality and MACE in
Hemodialysis and PD Patients
Variables
Hemodialysis PD
Mortality MACE Mortality MACE
HR 95% CI P Value HR 95% CI P Value HR 95% CI P Value HR 95% CI P Value
Age, y (per decade) 1.49 1.26 to 1.76 <0.001 1.44 1.13 to 1.83 0.004
Comorbidities
CHD 1.67 1.15 to 2.44 0.008 1.60 1.01 to 2.54 0.045
Respiratory 1.56 0.99 to 2.48 0.057 1.82 1.06 to 3.12 0.031
PVD 1.94 1.09 to 3.45 0.024
Laboratory values
hs-cTnT quintile
1 (≤31 ng/L) Reference Reference
2 (32–49 ng/L) 1.73 0.74 to 4.05 0.206 2.18 0.88 to 5.39 0.092 0.55 0.14 to 2.10 0.383 3.81 0.78 to 18.53 0.097
3 (50=72 ng/L) 2.36 1.03 to 5.44 0.043 2.61 1.06 to 6.45 0.038 2.49 0.89 to 6.93 0.081 3.53 0.71 to 17.52 0.124
4 (73–108 ng/L) 2.46 1.11 to 5.47 0.027 2.19 0.90 to 5.37 0.086 3.54 1.25 to 10.05 0.017 5.55 1.11 to 27.63 0.037
5 (≥109 ng/L) 3.55 1.64 to 7.70 0.001 3.27 1.40 to 7.62 0.006 5.63 2.02 to 15.67 0.001 10.66 2.27 to 50.14 0.003
Albumin (per 10 g/L) 0.56 0.36 to 0.85 0.007 0.61 0.38 to 0.98 0.040 0.56 0.33 to 0.95 0.031
CRP quintile
1 (≤1.6 mg/L) Reference Reference
2 (1.7–3.6 mg/L) 1.34 0.57 to 3.14 0.497 0.77 0.24 to 2.55 0.672
3 (3.7–7.3 mg/L) 2.06 0.86 to 4.94 0.107 1.91 0.63 to 5.84 0.255
4 (7.4–16.8 mg/L) 1.24 0.49 to 3.16 0.654 0.82 0.20 to 3.31 0.783
5 (≥16.9 mg/L) 3.62 1.62 to 8.07 0.002 3.60 1.29 to 10.03 0.014
Dialysis vintage, y 1.05 1.00 to 1.10 0.045
Nonsigniﬁcant factors not shown in the table included hepatitis B/C, DVT/PE, malignancy, neurological disease, calcium, phosphate, magnesium, hemoglobin, and PTH. CHD indicates
coronary heart disease; CI, conﬁdence interval; CRP, C-reactive protein; DVT, deep vein thrombosis; HR, hazard ratio; hs-cTnT, high-sensitivity cardiac troponin T; MACE, major adverse
cardiovascular events; PD, peritoneal dialysis; PE, pulmonary embolism; PTH, parathyroid hormone; PVD, peripheral vascular disease.
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greater than that of other known clinical risk factors, such as
sex, history of diabetes mellitus, and CHD, in the multivariable
analysis. When adding hs-cTnT to clinical parameters in the
ROC analysis, it improved the prognostic performance of
clinical parameters signiﬁcantly.
hs-cTnT and CRP Levels Are Different in
Hemodialysis Patients Compared With PD
Patients
There are a few differences between hemodialysis and PD
patients that are worthwhile noting. First, hemodialysis patients
had a higher baseline hs-cTnT and CRP level than PD patients,
even though prevalence of CHD in the 2 cohorts is similar. It is
well established that hemodialysis patients have high baseline
troponin levels, without acutemyocardial infarction or coronary
artery disease.32–34 The reason for this is controversial, but
there is emerging evidence suggesting that hemodialysis-
induced myocardial stunning may be the cause of high troponin
levels in these patients, and it may contribute to the increased
adverse outcomes.35,36 On the other hands, PD is not
associated with myocardial stunning.37 However, PD is not
completely benign. It may still induce subclinical myocardial
injury and hence result in their higher-than-normal baseline
value.38 Second, we found that CRP was a predictor in PD
patients, but not hemodialysis patients. One possible reason
may be that hemodialysis patients are subject to more factors
such as dialysis membrane incompatibility and dialysate
backﬂow, which can cause larger CRP ﬂuctuations than PD
patients. Third, there is less hs-cTnT variability in hemodialysis
patients than PD patients. It would be interesting to see
whether variation in hs-cTnT level can also predict outcome.
However, this analysis is beyond the scope of this study.
hs-cTnT as a Risk Predictor in Patients Without
Known CHD
In the subgroup of patients without CHD, even though they
had lower hs-cTnT than patients with CHD, the majority still
had elevated hs-cTnT. This group of asymptomatic patients
still had poor survival, and the higher their hs-cTnT, the higher
the risk of mortality or MACE. There has been 1 study
showing similar results in PD patients with traditional troponin
assay.39 The mechanism for this is unclear. However, there is
emerging evidence that elevated hs-cTnT may indicate
subclinical myocardial stunning in hemodialysis patients
rather than coronary artery disease.36 In PD patients, it has
also been proposed that the elevated troponin could be
attributed to subclinical myocardial injury.38 Given that this
population is not usually under stringent cardiac monitoring,
they may beneﬁt the most from biomarker risk stratiﬁcation
and subsequent referral to a cardiologist.Ta
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Limitations
This is a single-center observational study, which may limit the
generalizability of our ﬁndings. The outcome data were based
on clinical records, and sudden death was considered a cardiac
death if no other cause was recognized. Cause of death was not
conﬁrmed by postmortem examination, but based on clinical
assessment. In addition, the focus of this study was not to
understand the underlying pathophysiology for elevated tro-
ponin; as such, echocardiographic and coronary angiographic
results or hemodynamic data during hemodialysis sessions was
not collected nor factored into the analysis.
Clinical Implications
Our study has several important clinical implications. First, we
conﬁrmed that increased level of hs-cTnT is an independent
predictor for mortality and MACE in both hemodialysis and PD
patients. Its prognostic value is better than CRP. The increased
risk of adverse outcomes with increased hs-cTnT quintiles did
not follow a linear relationship. The increased risk only became
signiﬁcant when hs-cTnT reached quintile 3 (50–72 ng/L), and
the HR peaked at quintile 5 (>108 ng/L). Second, CRP is an
independent predictor for mortality and MACE in PD patients
only. The increased risk was only associated with patients with
CRP in quintile 5 (>16.8 mg/L), but not lower quintiles. Third, in
PD patients, where there is a paucity of information, we have
shown that both CRP and hs-cTnT are independent predictors
for both mortality and MACE. Adding hs-cTnT to clinical
parameters signiﬁcantly improved the risk prediction of clinical
parameters. Fourth, the frequency of hs-cTnT measurement
should be at least yearly for PD patients to establish baseline
given the level increases signiﬁcantly. For hemodialysis
patients, a less-frequent measurement may be acceptable
given that the change over time is minimal.
Future work should assess the cost-effectiveness of
routine measures of these biomarkers in clinical practice,
and how they can be used to improve clinical management
and therapeutic intervention.
Acknowledgments
The authors thank Dr Karen Byth for her assistance in the statistical
analysis.
Disclosures
None.
References
1. ANZDATA Registry. 38th report, Chapter 3: mortality in end stage kidney
disease [Internet]. Australia and New Zealand Dialysis and Transplant Registry.
2016. Available at: http://www.anzdata.org.au/anzdata/AnzdataReport/
38thReport/c03_anzdata_deaths_v2.0_20160112_web.pdf. Accessed December
15, 2016.
2. Herzog CA, Asinger RW, Berger AK, Charytan DM, Diez J, Hart RG, Eckardt KU,
Kasiske BL, McCullough PA, Passman RS, DeLoach SS, Pun PH, Ritz E.
Cardiovascular disease in chronic kidney disease. A clinical update from
Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int.
2011;80:572–586.
3. Akchurin OM, Kaskel F. Update on inﬂammation in chronic kidney disease.
Blood Purif. 2015;39:84–92.
4. Michos ED, Wilson LM, Yeh HC, Berger Z, Suarez-Cuervo C, Stacy SR, Bass EB.
Prognostic value of cardiac troponin in patients with chronic kidney disease
without suspected acute coronary syndrome: a systematic review and meta-
analysis. Ann Intern Med. 2014;161:491–501.
5. Khan NA, Hemmelgarn BR, Tonelli M, Thompson CR, Levin A. Prognostic value
of troponin T and I among asymptomatic patients with end-stage renal
disease: a meta-analysis. Circulation. 2005;112:3088–3096.
6. Apple FS, Collinson PO. Analytical characteristics of high-sensitivity cardiac
troponin assays. Clin Chem. 2012;58:54–61.
7. Sherwood MW, Kristin Newby L. High-sensitivity troponin assays: evidence,
indications, and reasonable use. J Am Heart Assoc. 2014;3:e000403. DOI: 10.
1161/JAHA.113.000403.
8. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inﬂammation,
aspirin, and the risk of cardiovascular disease in apparently healthy men. N
Engl J Med. 1997;336:973–979.
Table 5. AUC for hs-cTnT, CRP, and Combined Clinical Parameters as Predictors of Outcomes at 3.5 Years
Outcomes
hs-cTnT CRP Clinical Parameters
P Value*
Clinical
Parameters+hs-cTnT
AUC 95% CI AUC 95% CI AUC 95% CI AUC 95% CI
All group Mortality 0.71 0.66 to 0.75 0.59 0.54 to 0.64 0.70 0.65 to 0.75 0.012 0.74 0.69 to 0.79
MACE 0.62 0.57 to 0.67 0.52 0.47 to 0.58 0.63 0.58 to 0.69 0.066 0.65 0.60 to 0.70
PD Mortality 0.77 0.67 to 0.85 0.58 0.48 to 0.68 0.69 0.59 to 0.78 0.002 0.84 0.75 to 0.90
MACE 0.66 0.57 to 0.75 0.55 0.45 to 0.64 0.69 0.59 to 0.78 0.332 0.71 0.61 to 0.79
Hemodialysis Mortality 0.67 0.61 to 0.73 0.60 0.53 to 0.66 0.72 0.66 to 0.78 0.251 0.74 0.67 to 0.79
MACE 0.60 0.53 to 0.66 0.50 0.44 to 0.57 0.63 0.57 to 0.69 0.570 0.64 0.57 to 0.70
AUC indicates area under the receiver operating curve; CI, conﬁdence interval; CRP, C-reactive protein; Hs-cTnT, high-sensitivity cardiac troponin T; MACE, major adverse cardiovascular
events; PD, peritoneal dialysis.
*P values presented here are for comparison between clinical parameters and clinical parameters+hs-cTnT. Clinical parameters used in the analysis included age, sex, dialysis vintage,
history of diabetes mellitus, coronary heart disease, and peripheral vascular disease.
DOI: 10.1161/JAHA.117.007876 Journal of the American Heart Association 12
Hs-cTnT and CRP in Dialysis Patients Chen et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on April 16, 2019
9. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and
coronary heart disease in the MRFIT nested case-control study. Multiple Risk
Factor Intervention Trial. Am J Epidemiol. 1996;144:537–547.
10. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all-
cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis.
2000;35:469–476.
11. deFilippi C, Wasserman S, Rosanio S, Tiblier E, Sperger H, Tocchi M,
Christenson R, Uretsky B, Smiley M, Gold J, Muniz H, Badalamenti J, Herzog C,
Henrich W. Cardiac troponin T and C-reactive protein for predicting prognosis,
coronary atherosclerosis, and cardiomyopathy in patients undergoing long-
term hemodialysis. JAMA. 2003;290:353–359.
12. Noh H, Lee SW, Kang SW, Shin SK, Choi KH, Lee HY, Han DS. Serum C-reactive
protein: a predictor of mortality in continuous ambulatory peritoneal dialysis
patients. Perit Dial Int. 1998;18:387–394.
13. Accredited facilities and labs. The National Association of Testing Authorities,
Australia (NATA). Available at: http://www.nata.com.au/nata/scopeinfo/?ke
y=2900. Accessed February 10, 2017.
14. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third
universal deﬁnition of myocardial infarction. Circulation. 2012;126:2020–
2035.
15. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two
or more correlated receiver operating characteristic curves: a nonparametric
approach. Biometrics. 1988;44:837–845.
16. Wolley M, Stewart R, Curry E, Davidson J, White H, Pilmore H. Variation in
and prognostic importance of troponin T measured using a high-sensitivity
assay in clinically stable haemodialysis patients. Clin Kidney J. 2013;6:402–
409.
17. McGill D, Talaulikar G, Potter JM, Koerbin G, Hickman PE. Over time, high-
sensitivity TnT replaces NT-proBNP as the most powerful predictor of death in
patients with dialysis-dependent chronic renal failure. Clin Chim Acta.
2010;411:936–939.
18. Artunc F, Mueller C, Breidthardt T, Twerenbold R, Peter A, Thamer C, Weyrich
P, Haering HU, Friedrich B. Sensitive troponins—which suits better for
hemodialysis patients? Associated factors and prediction of mortality. PLoS
One. 2012;7:e47610.
19. Artunc F, Nowak A, Muller C, Peter A, Heyne N, Haring HU, Friedrich B.
Mortality prediction using modern peptide biomarkers in hemodialysis patients
—a comparative analysis. Kidney Blood Press Res. 2014;39:563–572.
20. Voroneanu L, Siriopol D, Nistor I, Apetrii M, Hogas S, Onofriescu M, Covic A.
Superior predictive value for NTproBNP compared with high sensitivity cTnT in
dialysis patients: a pilot prospective observational study. Kidney Blood Press
Res. 2014;39:636–647.
21. Apple FS. Predictive value of cardiac troponin I and T for subsequent death in
end-stage renal disease. Circulation. 2002;106:2941–2945.
22. Fahim MA, Hayen AD, Horvath AR, Dimeski G, Coburn A, Tan KS, Johnson DW,
Craig JC, Campbell SB, Hawley CM. Biological variation of high sensitivity
cardiac troponin-T in stable dialysis patients: implications for clinical practice.
Clin Chem Lab Med. 2015;53:715–722.
23. Apple FS, Murakami MM, Pearce LA, Herzog CA. Multi-biomarker risk
stratiﬁcation of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-
reactive protein, and cardiac troponin T and I in end-stage renal disease for all-
cause death. Clin Chem. 2004;50:2279–2285.
24. Bazeley J, Bieber B, Li Y, Morgenstern H, de Sequera P, Combe C, Yamamoto
H, Gallagher M, Port FK, Robinson BM. C-reactive protein and prediction of 1-
year mortality in prevalent hemodialysis patients. Clin J Am Soc Nephrol.
2011;6:2452–2461.
25. Kawaguchi T, Tong L, Robinson BM, Sen A, Fukuhara S, Kurokawa K, Canaud B,
Lameire N, Port FK, Pisoni RL. C-reactive protein and mortality in hemodialysis
patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Nephron Clin Pract. 2011;117:c167–c178.
26. Kato A, Takita T, Furuhashi M, Maruyama Y, Hishida A. Comparison of serum
albumin, C-reactive protein and carotid atherosclerosis as predictors of 10-
year mortality in hemodialysis patients. Hemodial Int. 2010;14:226–232.
27. Boulier A, Jaussent I, Terrier N, Maurice F, Rivory JP, Chalabi L, Boularan AM,
Delcourt C, Dupuy AM, Canaud B, Cristol JP. Measurement of circulating
troponin Ic enhances the prognostic value of C-reactive protein in haemodial-
ysis patients. Nephrol Dial Transplant. 2004;19:2313–2318.
28. Dekker FW, de Mutsert R, van Dijk PC, Zoccali C, Jager KJ. Survival analysis:
time-dependent effects and time-varying risk factors. Kidney Int.
2008;74:994–997.
29. Meuwese CL, Stenvinkel P, Dekker FW, Carrero JJ. Monitoring of inﬂammation
in patients on dialysis: forewarned is forearmed. Nat Rev Nephrol.
2011;7:166–176.
30. Hassan HC, Howlin K, Jefferys A, Spicer ST, Aravindan AN, Suryanarayanan G,
Hall BM, Cleland BD, Wong JK, Suranyi MG, Makris A. High-sensitivity troponin
as a predictor of cardiac events and mortality in the stable dialysis population.
Clin Chem. 2014;60:389–398.
31. Liu SH, Li YJ, Wu HH, Lee CC, Lin CY, Weng CH, Chen YC, Chang MY, Hsu HH,
Fang JT, Hung CC, Yang CW, Tian YC. High-sensitivity C-reactive protein
predicts mortality and technique failure in peritoneal dialysis patients. PLoS
One. 2014;9:e93063.
32. Ooi DS, House AA. Cardiac troponin T in hemodialyzed patients. Clin Chem.
1998;44:1410–1416.
33. Conway B, McLaughlin M, Sharpe P, Harty J. Use of cardiac troponin T in
diagnosis and prognosis of cardiac events in patients on chronic haemodial-
ysis. Nephrol Dial Transplant. 2005;20:2759–2764.
34. Obialo CI, Sharda S, Goyal S, Oﬁli EO, Oduwole A, Gray N. Ability of troponin T
to predict angiographic coronary artery disease in patients with chronic kidney
disease. Am J Cardiol. 2004;94:834–836.
35. Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced cardiac
injury: determinants and associated outcomes. Clin J Am Soc Nephrol.
2009;4:914–920.
36. Breidthardt T, Burton JO, Odudu A, Eldehni MT, Jefferies HJ, McIntyre CW.
Troponin T for the detection of dialysis-induced myocardial stunning in
hemodialysis patients. Clin J Am Soc Nephrol. 2012;7:1285–1292.
37. Selby NM, McIntyre CW. Peritoneal dialysis is not associated with myocardial
stunning. Perit Dial Int. 2011;31:27–33.
38. Wang AY, Lam CW, Yu CM, Wang M, Chan IH, Lui SF, Sanderson JE. Troponin T,
left ventricular mass, and function are excellent predictors of cardiovascular
congestion in peritoneal dialysis. Kidney Int. 2006;70:444–452.
39. Han SH, Choi HY, Kim DK, Moon SJ, Lee JE, Yoo TH, Kim BS, Kang SW, Choi KH,
Lee HY, Han DS. Elevated cardiac troponin T predicts cardiovascular events in
asymptomatic continuous ambulatory peritoneal dialysis patients without a
history of cardiovascular disease. Am J Nephrol. 2009;29:129–135.
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
DOI: 10.1161/JAHA.117.007876 Journal of the American Heart Association 13
Hs-cTnT and CRP in Dialysis Patients Chen et al
D
ow
nloaded from
 http://ahajournals.org by on April 16, 2019
SUPPLEMENTAL MATERIAL
D
ow
nloaded from
 http://ahajournals.org by on April 16, 2019
Table S1. Baseline characteristics and outcomes across quintiles based on hs-cTnT. 
Q1 (N=118) Q2 (N=113) Q3 (N=118) Q4 (N=111) Q5 (N=114) P Value 
Hs-
cTnT<=31ng/L 32-49ng/L 50-72ng/L 73-108ng/L 109+ng/L 
Age, years 57.7 (48-68.8) 67.2 (56.8-75.1) 68.0 (56.3-75.0) 68.3 (61.0-75.4) 65.0 (57.5-73.5) <0.001 
Sex, male 49 (41.5) 57 (50.2) 75 (63.6) 74 (66.7) 87 (76.3) <0.001 
Comorbidities 
      Diabetes 38 (32.2) 56 (49.6) 62 (52.5) 70 (63.1) 84 (73.7) <0.001 
CHD 27 (22.9) 46 (40.7) 50 (42.4) 45 (40.5) 60 (52.6) <0.001 
Hepatitis B/C 10 (8.5) 6 (5.3) 5 (4.2) 6 (5.4) 4 (3.5) 0.486 
DVT/PE 8 (6.8) 6 (5.3) 7 (5.9) 7 (6.3) 5 (4.4) 0.938 
Malignancy 15(12.7) 8 (7.1) 16 (13.6) 11 (9.9) 19 (16.7) 0.229 
Respiratory 13 (11.0) 10 (8.8) 23 (19.5) 15 (13.5) 24 (21.1) 0.041 
Neurological 13 (11.0) 16 (14.2) 14 (11.9) 20 (18.0) 13 (11.4) 0.481 
PVD 7 (5.9) 7 (6.2) 6 (5.1) 9 (8.1) 13 (11.4) 0.37 
Laboratory values 
      Albumin, g/L 40 (37-42) 39 (35-42) 40 (36-42) 39 (36-42) 39 (35-42) 0.092 
Calcium, mmol/L 2.27 (2.17-2.37) 2.27 (2.14-2.36) 2.30 (2.16-2.42) 2.27 (2.15-2.39) 2.28 (2.21-2.38) 0.348 
Phosphate, mmol/L 1.53 (1.26-1.99) 1.67 (1.31-2.11) 1.71 (1.38-2.06) 1.64 (1.35-1.98) 1.72 (1.31-2.11) 0.347 
Magnesium, 
mmol/L 0.88 (0.81-0.97) 0.91 (0.81-1.05) 0.89 (0.81-0.99) 0.93 (0.83-1.04) 0.91 (0.81-0.99) 0.360 
Hemoglobin, g/L 115 (102-122) 112 (98-123) 116 (106-126) 113 (104-125) 114 (101-125) 0.280 
CRP, mg/L 4.2 (2.4-11.1) 4.8 (1.6-13.7) 5.3 (1.9-11.3) 5.1 (1.9-13.4) 5.0 (2.7-17.1) 0.420 
PTH, pmol/L 35.7 (20.5-75.2) 29.5 (11.8-49.9) 34.3 (18.6-56.8) 35.6 (15.1-58.2) 24.3 (12.5-55.7) 0.043 
Dialysis Vintage, 
years 0.8 (0.1-2.4) 1.2 (0.4-3.2) 1.3 (0.2-4.3) 2.1 (0.4-5.5) 1.6 (0.4-3.8) 0.011 
Outcomes 
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Mortality 13 (11.0) 23 (20.4) 36 (30.5) 43 (38.7) 61 (53.5) 
MACE 9 (7.6) 22 (19.5) 21 (17.8) 22 (19.8) 37 (32.5) 	 	 DVT indicates deep vein thrombosis; PE, pulmonary embolism; CHD, coronary heart disease; PVD, peripheral vascular disease; 	
hs-cTnT, high sensitivity cardiac troponin T; CRP, C-reactive protein; PTH, parathyroid hormone; MACE, major adverse 	 cardiovascular events.  
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Table S2. Baseline characteristics and outcomes across quintiles based on CRP. 
Q1 (N=114) Q2 (N=115) Q3 (N=114) Q4 (N=109) Q5 (N=113) P Value 
CRP<=1.6mg/L 1.7-3.6mg/L 3.7-7.3mg/L 7.4-16.8mg/L 16.9+mg/L 
Age, years 65.0 (56.6-71.6) 66.0 (53.7-73.6) 67.1 (53.8-75) 66.1 (53-73.4) 66.3 (57.2-75.7) 0.958 
Sex, male 70 (61.4) 66 (57.4) 64 (56.1) 68 (62.4) 69 (61.1) 0.843 
Comorbidities 
      Diabetes 61 (53.5) 69 (60.0) 71 (62.3) 51 (46.8) 56 (49.6) 0.111 
CHD 30 (26.3) 47 (40.9) 47 (41.2) 40 (36.7) 62 (54.9) <0.001 
Hepatitis B/C 12 (10.5) 5 (4.3) 3 (2.6) 6 (5.5) 5 (4.4) 0.092 
DVT/PE 5 (4.4) 4 (3.5) 8 (7.0) 12 (11.0) 4 (3.5) 0.087 
Malignancy 8 (7.0) 15 (13.0) 13 (11.4) 20 (18.3) 11 (9.7) 0.116 
Respiratory 10 (8.8) 18 (15.7) 15 (13.2) 20 (18.3) 21 (18.6) 0.199 
Neurological 12 (10.5) 17 (14.8) 16 (14.0) 15 (13.8) 16 (14.2) 0.898 
PVD 3 (2.6) 10 (8.7) 8 (7.0) 6 (5.5) 14 (12.4) 0.059 
Laboratory values 
      Hs-cTnT, ng/L 56 (34-91) 62 (37-105) 60 (35-108) 52 (31-77) 74 (44-121) <0.001 
Albumin, g/L 40 (36-42) 40 (37-43) 40 (37-42) 39 (36-42.5) 38 (43-41) 0.010 
Calcium, mmol/L 2.26 (2.13-2.38) 2.29 (2.16-2.39) 2.30 (2.21-2.42) 
2.28 (2.13-
2.365) 2.26 (2.16-2.36) 0.148 
Phosphate, mmol/L 1.64 (1.33-1.94) 1.68 (1.4-2.12) 1.61 (1.32-2.08) 1.60 (1.24-2.01) 1.72 (1.41-2.10) 0.253 
Magnesium, mmol/L 0.91 (0.82-1.01) 0.92 (0.85-1.00) 0.92 (0.81-1.04) 0.86 (0.80-1.00) 0.89 (0.80-0.98) 0.189 
Hemoglobin, g/L 113 (105-123) 116(104-125) 114 (103-123) 113 (106-125) 110 (99-122) 0.363 
PTH, pmol/L 24.1 (13.0-44.9) 35.4 (13.9-62.7) 37.4 (16.7-74.5) 33.5 (13.3-65.2) 33.0 (15.3-51.9) 0.104 
Dialysis Vintage, 
years 1.0 (0.2-3.1) 0.9 (0.2-2.9) 1.5 (0.2-3.5) 1.6 (0.5-3.9) 2.3 (0.5-5.9) 0.009 
Outcomes 
Mortality 21 (18.4) 30 (26.1) 35 (30.7) 33 (30.3) 54 (47.8) 
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MACE 17 (14.9) 19 (16.5) 28 (24.6) 18 (16.5) 28 (24.8) 
 DVT indicates deep vein thrombosis; PE, pulmonary embolism; CHD, coronary heart disease; PVD, peripheral vascular disease; 
hs-cTnT, high sensitivity cardiac troponin T; CRP, C-reactive protein; PTH, parathyroid hormone; MACE, major adverse 
cardiovascular events.  
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